AstraZeneca plans new Oxford vaccine trial to prove jab works on all ages
More volunteers will be recruited to test half-dose regimen as critics question latest results
A fresh global trial of the Oxford Covid-19 vaccine is being launched to clarify how effectively the jab protects older age groups - and banish doubts that have emerged since preliminary results were published on Monday.
“The company wants the new test to confirm the 90% efficacy rate that the shot showed in a portion of an existing trial,” Bloomberg reports.
That impressive rate was the result of an error, when a sub-group of about 2,700 trial subjects were given a half dose of the vaccine followed by a full booster dose, instead of the two full doses received by other participants.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
People in the sub-group were found to be the least likely to fall ill with Covid - but were all under the age of 55, and therefore less vulnerable to the coronavirus, health officials have revealed.
“The timeline for regulatory approval and rollout of the vaccine in the UK and Europe should not be affected” by the new testing push, The Guardian reports.
In the US, however, questions have been asked about whether AstraZeneca’s interim data tells the whole story.
“The problems start with the fact that Monday’s announcement did not present results from a single, large-scale, Phase 3 clinical trial,” says Wired. Instead, it included results from two separate trials, one in the UK and one in Brazil, which makes it hard to be sure researchers haven’t “cherry-picked the data”, the magazine adds.
AstraZeneca has pledged to publish its full results in a peer-reviewed journal as soon as possible.
Despite the urgency created by the mounting Covid-19 death toll, many experts have “called for patience”, Politico reports. Most believe that the full data will confirm the effectiveness of the Oxford vaccine.
And while some questions must still be answered, the recent vaccine trial results are “very good news”, says Professor Peter Openshaw of Imperial College London.
He told the BBC: “It is remarkable that each of the trials that are now reporting shows protection, which we did not know was going to be possible.”
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Italian senate passes law allowing anti-abortion activists into clinics
Under The Radar Giorgia Meloni scores a political 'victory' but will it make much difference in practice?
By Chas Newkey-Burden, The Week UK Published
-
Magazine interactive crossword - May 3, 2024
Puzzles and Quizzes Issue - May 3, 2024
By The Week US Published
-
Magazine solutions - May 3, 2024
Puzzles and Quizzes Issue - May 3, 2024
By The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published